Search Results
Mar 27, 2026, 13:15 ET Le Critical Path Institute lance l'initiative « One to Millions » pour redessiner l'avenir de la médecine individualisée à l'échelle mondiale.
et en partageant systématiquement les données pour développer des médicaments plus sûrs et plus efficaces. »L'intégration de données probantes post-autorisation dans le paradigme de développement est une caractéristique déterminante de l'initiative. L'intégration directe de données longitudinales
More news about: Critical Path Institute
Mar 27, 2026, 12:59 ET Hoag Advances Plans for Organ Transplant Center
similar population, has two liver transplant programs.Moreover, Hoag is one of the few hospitals in the region offering coordinated pre- and post-transplant care for patients receiving transplant surgery elsewhere. This means that to receive a transplant, patients must leave their supportive Hoag
More news about: Hoag
Mar 27, 2026, 12:30 ET Deccan AI Raises $25 Million to Build 'Super Accurate AI'
GenAI data company that runs the post–training and production layer for labs and enterprises – from expert feedback and RL environments to managed AI workforces and monitoring. It has quietly become the gold–standard data provider for post–training. Built on top of Deccan AI Experts,
More news about: Deccan AI
Mar 27, 2026, 10:15 ET MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value
https://www.healthcare.digital/single-post/medtech-2026-trends-deals-and-investmentsLogo -
More news about: Equity Insider
Mar 27, 2026, 10:00 ET What are the Best Companies to Start and Grow a Career? Independent "Where You Work Matters" Study Recognizes Fisher Investments
Strategy" column for over 32 years until 2017, making him the longest running columnist in its history. He now writes monthly for the New York Post and unique columns in native language, varying by country, in 28 major nations, spanning more countries and more total volume than any other columnist
More news about: Fisher Investments
Mar 27, 2026, 09:48 ET ADAMA Reports Fourth Quarter and Full Year 2025 Results
2025 launches of differentiated products included:EDAPTIS® (Italy) and PULIMAISI™(China): Two innovative post-emergence herbicides combining both Pinoxaden and Mesosulfuron-methyl to provide effective control of a broad spectrum of grasses, including resistant
More news about: ADAMA Ltd.
Mar 27, 2026, 09:35 ET NatGold Digital's Appointment of ECM Capital Advisors Expands Its Global Development Network for Qualifying Gold Resources
on Baseline Intrinsic Value, the Company is focused on expanding its pipeline of qualifying gold resources to support anticipated demand growth post-launch."ECM brings a level of experience, global reach and credibility that is highly aligned with what NatGold Digital is building," said Andrés
More news about: NatGold Digital Ltd.
Mar 27, 2026, 09:15 ET Scalable Biotech Manufacturing Unlocks a $14B Market
evaluating its Revita® duodenal ablation procedure for post-GLP-1 weight maintenance, with topline 6-month data expected in early Q4 2026 and a potential FDA De Novo marketing application submission targeted for late Q4 2026. New post-hoc analyses from the REMAIN-1 Midpoint Cohort show
More news about: USA News Group
Mar 27, 2026, 09:00 ET It All Started with a Chinese Candy Wrapper: A Sweet Story in Milan
the encounter, Sun shared her story on social media, along with the hotel's location for anyone who wanted to help.To everyone's surprise, the post quickly went viral. In the comments, some Chinese netizens realized that they were the very ones who left the Chinese crispy candies for the front desk
More news about: China.org.cn
Mar 27, 2026, 09:00 ET UCB Presents New BIMZELX® (bimekizumab-bkzx) Data at AAD Demonstrating High Rates of Durable and Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis
Post hoc analyses of BIMZELX (bimekizumab-bkzx) using the first consensus definition of psoriasis on-treatment remission:Published by the National Psoriasis Foundation (NPF), this first consensus definition requires stringent criteria for complete skin
More news about: UCB
Mar 27, 2026, 09:00 ET UCB Announces New BIMZELX® (bimekizumab-bkzx) Data at AAD Showing Durable Symptom Control Throughout Three Years in Hidradenitis Suppurativa
treated with BIMZELX had no acute exacerbation of symptoms, known as 'flares,' to three years in a post hoc analysis*Improved outcomes with earlier treatment: Of those treated with BIMZELX, a post hoc analysis showed shorter disease duration and lower severity yielded improved outcomes at three
More news about: UCB
Mar 27, 2026, 09:00 ET Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis
previously reported long-term results for EBGLYSS for patients with moderate-to-severe atopic dermatitis. In addition, a post-hoc analysis presented at Maui Derm Hawaii 2026 on EASI-75 stable responders showed less than one flare per patient per year with EBGLYSS monthly maintenance
More news about: Eli Lilly and Company
Mar 27, 2026, 08:33 ET Is This a Real Sitcom? Comedian Concrete Leaves Fans Guessing With "Chair-Man of The Board"
Instagram post teasing what appears to be a sitcom titled Chair-Man of the Board. The post, which dropped on Concrete's Instagram earlier this week, introduces fans to "Jerry," a character whose
More news about: Concrete
Mar 27, 2026, 08:00 ET Otsuka Pharmaceutical to Acquire Transcend Therapeutics
Otsuka portfolio in psychiatric and neurological fields and aims to accelerate development of Transcend's portfolio, including the TSND-201 program for post-traumatic stress disorder (PTSD) –TOKYO and NEW YORK, March 27, 2026
More news about: Otsuka Pharmaceutical Co.; Transcend Therapeutics
Mar 27, 2026, 07:55 ET Mega Matrix Inc. Announces Strategic Initiative to Advance AI-Driven Short Drama Production and Enterprise AI Deployment
www.megamatrix.io) to host social media disclosures and/or links to/from such disclosures. The information we post through these social media channels may be deemed material. Accordingly, investors should monitor these social media channels in addition to following
More news about: Mega Matrix Inc.
Mar 27, 2026, 06:45 ET Neutrogena®, Aveeno® and Rogaine® Release New Dermatology Research and Clinical Skincare Innovations on Healthy Aging, Moisturization, Sun Protection and Acne
A panel titled Moisture in Motion: How Hydro Boost Enhances Treatment Journeys From Acne to Procedures will dive into the pre- and post-procedural clincal results of the
More news about: Kenvue Inc.
Mar 27, 2026, 05:45 ET GeeLark is the Revolution
beyond simple AIGC to prioritize the "how" of global scaling:RPA: GeeLark's Robotic Process Automation doesn't just post; it interacts. From scrolling and liking to complex account-warming flows, the RPA engine operates within the cloud-phone kernel to generate the authentic
More news about: GeeLark
Mar 27, 2026, 05:41 ET Notice to Annual General Meeting of shareholders in Loomis AB
Euroclear Sweden AB, concerning the circumstances on Monday April 27, 2026; andnotify the company of their intention to participate in the AGM by post to Loomis AB, "AGM", c/o Euroclear Sweden AB, P.O. Box 191, SE-101 23 Stockholm, by telephone + 46 8 402 90 72 or via the company website
More news about: Loomis AB
Mar 27, 2026, 03:00 ET TradeZero breidt Europese aanwezigheid uit naar België, Luxemburg, Noorwegen en Denemarken
traders en beleggers in heel Europa te vergroten. Via TradeZero Europe profiteren klanten van unieke platformfunctionaliteiten, uitgebreide pre- en post-marketsessies en echte bidirectionele long- en shorthandel
More news about: TradeZero
Mar 26, 2026, 17:53 ET GEMI UPDATE: Hagens Berman Alerts Gemini Space Station (GEMI) Investors to Securities Class Action Following 75% Post-IPO Collapse
multimedia:https://www.prnewswire.com/news-releases/gemi-update-hagens-berman-alerts-gemini-space-station-gemi-investors-to-securities-class-action-following-75-post-ipo-collapse-302726633.htmlSOURCE
More news about: Hagens Berman Sobol Shapiro LLP
Mar 26, 2026, 17:44 ET NAVN SHAREHOLDER ALERT: Lawsuit Alleges Navan's (NAVN) IPO Materials Omitted to Surge in Sales & Marketing Expenses - Hagens Berman
revenue and Gross Booking Volume (GBV) growth touted in the IPO documents.CFO Abrupt Departure: On December 15, 2025, just six weeks post-IPO, Navan revealed the sudden departure of its CFO, Amy Butte.63% Value Erosion: On the news of the expense spike and CFO exit, Navan's
More news about: Hagens Berman Sobol Shapiro LLP
Mar 26, 2026, 16:40 ET Douglas Elliman Launches Elliman Yachts, Expanding Its Luxury Lifestyle Platform
Additional information concerning Douglas Elliman Inc. is available on its website, investors.elliman.com.Investors and others should note that we may post information about Douglas Elliman Inc. on our website at
More news about: Douglas Elliman
Mar 26, 2026, 16:05 ET Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
sudden death. IBTROZI prolongs the QTc interval in a concentration-dependent manner.In patients who received IBTROZI and underwent at least one post baseline ECG, QTcF increase of >60 msec compared to baseline and QTcF >500 msec occurred in 13% and 2.6% of patients, respectively. 3.4% of patients
More news about: Nuvation Bio Inc.; Eisai Co., Ltd
Mar 26, 2026, 14:17 ET Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
from these treatments by systematically collecting and sharing data to inform the development of safer, more effective medicines."Integrating post-authorization evidence generation into the development paradigm is a defining feature of the initiative. Embedding longitudinal registries directly
More news about: Critical Path Institute
Mar 26, 2026, 14:01 ET Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
from these treatments by systematically collecting and sharing data to inform the development of safer, more effective medicines."Integrating post-authorization evidence generation into the development paradigm is a defining feature of the initiative. Embedding longitudinal registries directly
More news about: Critical Path Institute